Oragenics EV/FCF

What does Oragenics do? Oragenics, Inc. develops novel antibiotics and treatments for infectious diseases and oral mucositis, targeting patients undergoing cancer therapy. The company focuses on product candidates including OG716 as an antibiotic, AG013 for oral mucositis treatment, and TerraCoV2 as an immunization candidate. Additional products like LPT3-04 for weight loss and SMaRT Replacement Therapy are also in development. Oragenics generates revenue through the development and potential commercialization of these pharmaceutical products, primarily targeting healthcare providers and patients seeking treatments for specific medical conditions. The company's product portfolio includes OG716, AG013, TerraCoV2, LPT3-04, and SMaRT Replacement Therapy, each addressing distinct medical needs. These products are developed for use in clinical settings, with AG013 specifically intended for cancer patients experiencing oral mucositis. The firm's focus on biopharmaceutical innovation positions it to secure partnerships or licensing agreements with larger pharmaceutical companies for product advancement and market entry. Oragenics targets healthcare providers, oncology centers, and patients requiring specialized treatments for infectious diseases and oral mucositis. The company's development pipeline includes both antibiotic therapies and immunization candidates, aiming to address unmet medical needs in these therapeutic areas. Revenue streams are expected to arise from future product sales, licensing deals, and potential collaborations with industry partners. Oragenics is one of the most popular companies on Eulerpool.